DK1687028T3 - Immunglobulinpræparater med øget stabilitet - Google Patents

Immunglobulinpræparater med øget stabilitet

Info

Publication number
DK1687028T3
DK1687028T3 DK04818790.0T DK04818790T DK1687028T3 DK 1687028 T3 DK1687028 T3 DK 1687028T3 DK 04818790 T DK04818790 T DK 04818790T DK 1687028 T3 DK1687028 T3 DK 1687028T3
Authority
DK
Denmark
Prior art keywords
increased stability
immunoglobulin preparations
immunoglobulin
preparations
stability
Prior art date
Application number
DK04818790.0T
Other languages
English (en)
Other versions
DK1687028T4 (da
Inventor
Reinhard Bolli
Gerhard Hodler
Regula Styger
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34429394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1687028(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Publication of DK1687028T3 publication Critical patent/DK1687028T3/da
Application granted granted Critical
Publication of DK1687028T4 publication Critical patent/DK1687028T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04818790.0T 2003-11-18 2004-11-17 Immunglobulinpræparater med øget stabilitet DK1687028T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03026539A EP1532983A1 (en) 2003-11-18 2003-11-18 Immunoglobulin preparations having increased stability
PCT/EP2004/013022 WO2005049078A2 (en) 2003-11-18 2004-11-17 Immunoglobulin preparations having increased stability

Publications (2)

Publication Number Publication Date
DK1687028T3 true DK1687028T3 (da) 2013-01-28
DK1687028T4 DK1687028T4 (da) 2015-12-21

Family

ID=34429394

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04818790.0T DK1687028T4 (da) 2003-11-18 2004-11-17 Immunglobulinpræparater med øget stabilitet
DK10177786.0T DK2364730T3 (da) 2003-11-18 2004-11-17 Immunglobulinpræparater med øget stabilitet

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10177786.0T DK2364730T3 (da) 2003-11-18 2004-11-17 Immunglobulinpræparater med øget stabilitet

Country Status (10)

Country Link
US (2) US8715652B2 (da)
EP (3) EP1532983A1 (da)
JP (1) JP4644203B2 (da)
KR (3) KR20120060924A (da)
AU (1) AU2004290899B2 (da)
CA (1) CA2545939C (da)
DK (2) DK1687028T4 (da)
ES (2) ES2580778T3 (da)
PL (2) PL1687028T5 (da)
WO (1) WO2005049078A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1532983A1 (en) † 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CA2610839C (en) 2005-06-14 2019-06-25 Amgen Inc. Self-buffering protein formulations
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
MX2009006594A (es) * 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
CN101679507A (zh) 2007-03-29 2010-03-24 艾博特公司 结晶抗人类il-12抗体
CA2692165A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
KR20150080038A (ko) * 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CN102202682B (zh) 2008-11-04 2015-08-19 Aska制药株式会社 含促卵泡激素的水性组合物
CA2742791A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
EA026112B1 (ru) 2009-09-17 2017-03-31 Бакстер Хелскэа, С.А. Стабильная композиция, содержащая гиалуронидазу и иммуноглобулин, и способы ее применения
JP6078344B2 (ja) * 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
ES2642512T3 (es) 2010-03-01 2017-11-16 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
JP2013523717A (ja) 2010-03-31 2013-06-17 ユニベルシテ ドゥ ジュネーブ 安定化された抗体調製物およびその使用
JP2013528570A (ja) 2010-03-31 2013-07-11 ユニベルシテ ドゥ ジュネーブ 安定化された抗体調製物およびその使用
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2961107B1 (fr) 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
MX351706B (es) * 2010-09-17 2017-10-25 Baxalta Inc Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro.
EP3058952A1 (en) * 2011-04-07 2016-08-24 Glaxosmithkline LLC Formulations with reduced viscosity
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
WO2013148686A2 (en) * 2012-03-26 2013-10-03 Sanofi Stable igg4 binding agent formulations
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20150157619A1 (en) * 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
EP2900262A1 (en) * 2012-09-27 2015-08-05 Octapharma AG Test for hemolytic potential of pharmaceutical products and formulations for risk minimization
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP4272763A3 (en) 2013-09-11 2024-02-14 Eagle Biologics, Inc. Liquid protein formulations containing organophosphates
US11471617B2 (en) 2014-04-03 2022-10-18 Csl Behring Ag Nebultzation of immunoglobulin
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2017164349A1 (ja) * 2016-03-25 2017-09-28 アステラス製薬株式会社 ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ'フラグメント含有医薬組成物
ES2770674T3 (es) * 2016-06-10 2020-07-02 Octapharma Ag Composición de inmunoglobulinas de alta concentración para aplicaciones farmacéuticas
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
SG11202110942SA (en) * 2019-04-18 2021-11-29 Janssen Biotech Inc Sialylated glycoproteins

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364792A1 (de) 1973-01-15 1974-07-18 South African Inventions Verfahren zum reinigen von gammaglobulin
JPS5420124A (en) 1977-07-14 1979-02-15 Green Cross Corp:The Preparation of gamma-globulin intravenous injection
US4186192A (en) 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
JPS5731623A (en) 1980-07-30 1982-02-20 Morishita Seiyaku Kk Production of gamma-globulin for intravenous injection
JPS56127321A (en) 1980-03-10 1981-10-06 Mochida Pharmaceut Co Ltd Preparation of gamma-globulin pharmaceutical
JPS56135418A (en) 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPS57128635A (en) 1981-01-30 1982-08-10 Morishita Seiyaku Kk Pharmaceutical preparation of gamma-globulin for venoclysis
US4360451A (en) * 1981-08-10 1982-11-23 Basf Wyandotte Corporation Amphoteric surfactant gels
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4439421A (en) * 1982-08-30 1984-03-27 Baxter Travenol Laboratories, Inc. Stabilized gamma globulin concentrate
JPS6042336A (ja) 1983-08-18 1985-03-06 Nippon Seiyaku Kk 免疫グロブリンの製造方法
JPS60120823A (ja) 1983-12-02 1985-06-28 Green Cross Corp:The ＩｇＧ単量体
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPH0825902B2 (ja) 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
DE3641115A1 (de) * 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
HUT54308A (en) 1989-04-04 1991-02-28 Lilly Co Eli Process for producing immunoglobulin conjugates and medicaments comprising same
JPH0341033A (ja) † 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
DE59009020D1 (de) * 1990-03-22 1995-06-08 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates.
JPH04346934A (ja) 1991-05-24 1992-12-02 Green Cross Corp:The γ−グロブリンの液状製剤
DE4118912C1 (da) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP2942412B2 (ja) 1991-12-26 1999-08-30 鐘紡株式会社 化粧料
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
DE59309332D1 (de) * 1993-12-27 1999-03-04 Rotkreuzstiftung Zentratrallab Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält
JPH07238036A (ja) 1994-02-28 1995-09-12 Green Cross Corp:The 静注用グロブリン液状組成物のグロブリン二量体増加抑制方法
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3765108B2 (ja) 1994-09-30 2006-04-12 三菱ウェルファーマ株式会社 静脈注射用グロブリン製剤
EP0792294A1 (en) 1994-11-16 1997-09-03 Baxter International Inc. Human antibodies to t-cell receptor peptides and methods for their preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
HU224222B1 (hu) * 1996-12-24 2005-06-28 Biogen Inc. Stabil folyékony interferon-készítményformák és eljárás interferon stabilizálására
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
ATE224203T1 (de) 1997-10-23 2002-10-15 Mitsubishi Pharma Corp Bei raumtemperatur lagerfähiges immunoglobolin- präparat für intravenöse injektion
US6162904A (en) * 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
EP1532983A1 (en) † 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
JP6078344B2 (ja) 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation

Also Published As

Publication number Publication date
US20070122402A1 (en) 2007-05-31
US8715652B2 (en) 2014-05-06
ES2398241T3 (es) 2013-03-14
EP2364730B1 (en) 2016-04-13
EP1687028A2 (en) 2006-08-09
WO2005049078A3 (en) 2005-07-07
DK1687028T4 (da) 2015-12-21
PL1687028T3 (pl) 2013-03-29
US8906368B2 (en) 2014-12-09
JP2007511566A (ja) 2007-05-10
EP2364730A2 (en) 2011-09-14
WO2005049078A2 (en) 2005-06-02
US20130102760A1 (en) 2013-04-25
AU2004290899B2 (en) 2009-11-19
KR20120060924A (ko) 2012-06-12
KR20100090731A (ko) 2010-08-16
EP1532983A1 (en) 2005-05-25
PL1687028T5 (pl) 2016-05-31
EP1687028B2 (en) 2015-11-04
PL2364730T3 (pl) 2016-12-30
AU2004290899A1 (en) 2005-06-02
EP1687028B1 (en) 2012-10-24
CA2545939C (en) 2013-12-24
EP2364730A3 (en) 2012-05-30
DK2364730T3 (da) 2016-08-01
CA2545939A1 (en) 2005-06-02
ES2580778T3 (es) 2016-08-26
JP4644203B2 (ja) 2011-03-02
KR100989288B1 (ko) 2010-10-22
ES2398241T5 (es) 2016-01-28
KR20060118495A (ko) 2006-11-23

Similar Documents

Publication Publication Date Title
DK1687028T3 (da) Immunglobulinpræparater med øget stabilitet
DK1699821T3 (da) Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
DK1599504T3 (da) Modificeret antistof
DE602004024728D1 (de) Schiebeelement
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
ATE395350T1 (de) Mit betainen stabilisierten aluminium-zirconium- glycin-antitranspirantien
NO20044347L (no) Anti-alfavbeta6-antistoff
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
NO20054136D0 (no) Imidazol-4-yl-etynyl-pyridin-derivater
DK1682493T3 (da) Amidoacetonitrilderivater
DE60318132D1 (de) Haarwaschmittel
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
DE60329874D1 (de) Haarwaschmittel
DK1613694T3 (da) Polyalkenaminer med forbedrede anvendelsesegenskaber
DE60319547D1 (de) Haarwaschmittel
IS8045A (is) Púrín-6-ón-afleiður
DK1685131T3 (da) Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner
DE602004017533D1 (de) Reissverschluss
DE602004004736D1 (de) Haarwaschmittel
DE60302757T2 (de) Kleinfahrzeug
DK1706373T3 (da) Amidoacetonitrilderivater
DE60335978D1 (de) Haarwaschmittel
DE60322439D1 (de) Anschlussstück
ITMI20042063A1 (it) Giunto
NO20053512D0 (no) IL-8-liknende proteiner